This article highlights the FDA approval of repotrectinib for adults with advanced ROS1-positive non-small cell lung cancer, based on the TRIDENT-1 study. The study showed a 79% objective response rate (ORR) in TKI-naive patients and a 38% ORR in those previously treated with a ROS1 TKI. The drug has shown to be effective even in patients with brain metastases. Participants, mostly female, Asian, and never-smokers, received daily repotrectinib and were evaluated every 8 weeks. Jessica J. Lin, MD, who is a primary investigator of TRIDENT-1, attending physician at the Center for Thoracic Cancers at Massachusetts General Hospital, and assistant professor of medicine at Harvard Medical School, suggests repotrectinib could potentially become a standard treatment option for this cancer type.

Reference: Rosa K. FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLC. OncLive. Published November 15, 2023. Accessed December 7, 2023. https://www.onclive.com/view/fda-approves-repotrectinib-for-locally-advanced-or-metastatic-ros1-nsclc